[go: up one dir, main page]

AR065803A1 - Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento - Google Patents

Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Info

Publication number
AR065803A1
AR065803A1 ARP080101155A ARP080101155A AR065803A1 AR 065803 A1 AR065803 A1 AR 065803A1 AR P080101155 A ARP080101155 A AR P080101155A AR P080101155 A ARP080101155 A AR P080101155A AR 065803 A1 AR065803 A1 AR 065803A1
Authority
AR
Argentina
Prior art keywords
lymphoma
cell
leukemia
hodgkin
cells
Prior art date
Application number
ARP080101155A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065803(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR065803A1 publication Critical patent/AR065803A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de (i) un polipéptido de IL-18 humana (SEQ ID N°:16); y (ii) un anticuerpo anti-CD, tal como rituximab u ofatumumab para preparar un medicamento util para tratar o prevenir cánceres para uso simultáneo o secuencial en cualquier orden. El cáncerse selecciona entre el grupo consistente en NHL (linfoma no Hodgkin), incluyendo leucemia linfoblástica de células B/linfoma, neoplasmas de células B maduras, leucemia Iinfocítica cronica da células B (CLL)/Iinfoma linfocítico pequeno (SLL),leucemia proIinfocítica de células B, linfoma linfoplasmacítico, linfoma de células del manto (MCL), linfoma folicuIar (FL), incluyendo FL de bajo grado, de grado intermedio y de alto grado, linfoma del centro folicular cutáneo, linfoma de células Bde zona marginal (tipo MALT, tipo nodal y esplénico), leucemia de células pilosas, linfoma de células B grande difuso, linfoma de Burkitt, plasmacitoma, mieloma de células plasmáticas, trastorno linfoproliferativo posterior a un trasplante,macroglobulinemia de Waldenstrom linfoma anaplásico de células grandes (ALCL), y linfoma no Hodgkin de células T.
ARP080101155A 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento AR065803A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
AR065803A1 true AR065803A1 (es) 2009-07-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101155A AR065803A1 (es) 2007-03-23 2008-03-19 Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP080101195A AR065818A1 (es) 2007-03-23 2008-03-25 Metodos de tratamiento del cancer mediante administracion de combinaciones de il-18 humana

Country Status (21)

Country Link
US (4) US20080274078A1 (es)
EP (3) EP2338514A1 (es)
JP (2) JP2010522200A (es)
KR (2) KR20100014530A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231114A1 (es)
BR (2) BRPI0808943A2 (es)
CA (2) CA2681851A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970885A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31265B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118733A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767207B2 (en) * 2000-02-10 2010-08-03 Abbott Laboratories Antibodies that bind IL-18 and methods of inhibiting IL-18 activity
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
TN2016000472A1 (en) 2014-04-25 2018-04-04 Pf Medicament Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
EP1292697B1 (en) 2000-06-15 2009-07-22 SmithKline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US20030202975A1 (en) * 2002-02-21 2003-10-30 Tedder Thomas F. Reagents and treatment methods for autoimmune diseases
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
CA2501757C (en) * 2002-10-08 2012-04-24 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
CA2502552C (en) * 2002-10-17 2019-02-12 Genmab A/S Human monoclonal antibodies against cd20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JP4753867B2 (ja) * 2003-04-15 2011-08-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ヒトｉｌ−１８を含むコンジュゲートおよびその置換変異体
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
WO2006111524A2 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
ES2530265T3 (es) * 2005-07-21 2015-02-27 Genmab A/S Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
CA2656836A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
WO2008033499A2 (en) * 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
JP2010522239A (ja) 2010-07-01
EP2136841A2 (en) 2009-12-30
EP2338514A1 (en) 2011-06-29
AR065818A1 (es) 2009-07-01
MA31265B1 (fr) 2010-03-01
CR11075A (es) 2010-03-22
CA2681851A1 (en) 2008-10-02
JP2010522200A (ja) 2010-07-01
BRPI0809079A2 (pt) 2019-03-06
EP2129398A1 (en) 2009-12-09
EA200970884A1 (ru) 2010-04-30
US20100196310A1 (en) 2010-08-05
TW200904469A (en) 2009-02-01
MX2009010269A (es) 2009-10-12
PE20090190A1 (es) 2009-03-22
CL2008000818A1 (es) 2008-09-26
NZ579179A (en) 2011-12-22
MA31264B1 (fr) 2010-03-01
WO2008118733A3 (en) 2008-11-27
TW200906436A (en) 2009-02-16
KR20100014530A (ko) 2010-02-10
AU2008231025A1 (en) 2008-10-02
PE20090184A1 (es) 2009-03-22
MX2009010271A (es) 2009-10-12
US20100111945A1 (en) 2010-05-06
WO2008118736A1 (en) 2008-10-02
US20090035258A1 (en) 2009-02-05
AU2008231114A1 (en) 2008-10-02
US20080274078A1 (en) 2008-11-06
EA200970885A1 (ru) 2010-02-26
BRPI0808943A2 (pt) 2014-08-26
SG171674A1 (en) 2011-06-29
DOP2009000208A (es) 2010-03-31
IL200863A0 (en) 2010-05-17
WO2008118733A2 (en) 2008-10-02
KR20100015798A (ko) 2010-02-12
IL200525A0 (en) 2010-04-29
EP2136841A4 (en) 2010-07-07
CN101678102A (zh) 2010-03-24
CR10996A (es) 2009-11-12
CL2008000842A1 (es) 2008-10-17
CA2681827A1 (en) 2008-10-02
EP2129398A4 (en) 2010-04-21
DOP2009000220A (es) 2009-10-31

Similar Documents

Publication Publication Date Title
AR065803A1 (es) Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
ZA202005556B (en) Cartyrin compositions and methods for use
NI201300119A (es) Uso del anticuerpo anti - cd19 inmunoconjugado con maitansinoide para el tratatamiento del síntoma tumores de células b.
CL2012002733A1 (es) Compuestos derivados de ácido 1-amino-2-ciclopropiletilborónico, inhibidores de proteasoma; composición farmacéutica; uso en el tratamiento del cáncer; procedimiento de preparacion; compuestos intermediarios.
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
MX370148B (es) Composiciones y su uso para inmunoterapia.
ECSP11009946A (es) Anticuerpos Anti-CD37
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
CL2012001387A1 (es) Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07)
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
DOP2010000037A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
CL2012001179A1 (es) Anticuerpo que se une específicamente linfopoyetina estromal tímica (tslp) humana o fragmento de unión a antígeno del mismo; ácido nucleico que lo codifica; vector de expresión; célula huésped; método de producción; composición que lo comprende; y su uso terapéutico como inmunosupresor.
AR080154A1 (es) Anticuerpos cd20 y su utilizacion
GT201300046A (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3)
PE20151780A1 (es) Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas
HN2012001846A (es) Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
MX2020011527A (es) Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
BR112015013260A2 (pt) uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
ECSP11011172A (es) Derivados de tieno [3,2-c]piridina como inhibidores de quinasas para el uso en el tratamiento del cáncer.
UY33349A (es) Nuevos compuestos de quinoxalina, quinolina y quinazolina, composiciones farmacéuticas que los contienen y uso de los mismos
AR083751A1 (es) Derivados de 1h-pirrolo[2,3-b]piridina y uso de los mismos en el tratamiento del cancer
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal